<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272311</url>
  </required_header>
  <id_info>
    <org_study_id>H08-35</org_study_id>
    <nct_id>NCT00272311</nct_id>
  </id_info>
  <brief_title>Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome</brief_title>
  <acronym>PAD</acronym>
  <official_title>A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Atlantic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Atlantic University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test higher versus lower doses of aspirin on markers of
      atherosclerosis in patients at risk of a first heart attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in
      patients who have survived a prior event as well as during an acute heart attack. Aspirin
      also prevents a first heart attack.

      Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or
      stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots.

      Our research is designed to explore whether higher doses of aspirin provide additional
      benefits on markers of atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inflammatory Markers From Baseline to 3 Months</measure>
    <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Platelet Biomarkers From Baseline to 3 Months</measure>
    <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Nitric Oxide Formation From Baseline to 3 Months</measure>
    <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
    <description>Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>81 mg Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>162 mg Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>325 mg Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>650 mg Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1300 mg Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Dosage</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 40 to 80 years, inclusive.

             2. No previous heart attack or a stroke, or other forms of these diseases.

             3. Have at least three of the five characteristics listed below, indicating presence
             of metabolic syndrome, as defined by NCEP-III:

               1. waist measuring more than 40 inches (for men) or more than 35 inches (for women),

               2. high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per
                  deciliter (mg/dl) in men or 50 mg/dl in women,

               3. triglyceride (TG) levels above 150 mg/dl,

               4. blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg
                  diastolic,

               5. fasting blood sugar greater than 110 mg/dl

        Exclusion Criteria:

          1. Patients taking greater than 81mg aspirin daily.

          2. Patients taking anti-platelet drugs such as clopidogrel or non-steroidal
             anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the
             last two weeks.

          3. Patients taking any of the following medications for less than 3 months, or who plan
             to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin
             receptor blockers, calcium channel blockers, or statins.

          4. Patients who are currently cigarette smokers.

          5. Women patients who are pregnant, planning to become pregnant, nursing a child, or
             taking hormone replacement therapy.

          6. Patients with any coagulation, bleeding or blood disorders.

          7. Patients who are sensitive or allergic to aspirin.

          8. Patients with documented history of any gastrointestinal disorders, including bleeding
             ulcers.

          9. Patients with any evidence of cancer or history of significant cardiovascular disease
             (including heart attack, stroke or drop attacks termed transient ischemic attacks
             (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease
             (PAD)), kidney, liver, lung, blood, or brain disorders.

         10. Patients with asthma, rhinitis, or nasal polyps.

         11. Patients with any abnormal laboratory value or physical finding that, in the view of
             the responsible clinician, may interfere with interpretation of the study results, be
             indicative of an underlying disease state, or compromise the safety.

         12. Patients with Class IV heart failure.

         13. Patients with severe aortic insufficiency, or aortic regurgitation.

         14. Patients with hearing loss or tinnitus.

         15. Patients with tremors which cause them not to be able to remain motionless for
             approximately 30 seconds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles H Hennekens, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Atlantic University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wendy R Schneider, MSN, CCRC</last_name>
    <role>Study Director</role>
    <affiliation>Florida Atlantic University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HeartDrug Research, LLC</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases--forgotten benefits? Expert Opin Pharmacother. 2004 Jan;5(1):109-15. Review.</citation>
    <PMID>14680440</PMID>
  </reference>
  <reference>
    <citation>Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989 Oct;80(4):749-56. Review.</citation>
    <PMID>2676237</PMID>
  </reference>
  <reference>
    <citation>Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 Sep 22;163(17):2006-10.</citation>
    <PMID>14504112</PMID>
  </reference>
  <reference>
    <citation>Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6.</citation>
    <PMID>810797</PMID>
  </reference>
  <reference>
    <citation>Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366-72.</citation>
    <PMID>7045161</PMID>
  </reference>
  <reference>
    <citation>Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987 Jan;69(1):180-6.</citation>
    <PMID>3790723</PMID>
  </reference>
  <reference>
    <citation>Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh. 1975 Jun 30;33(3):444-56.</citation>
    <PMID>1154306</PMID>
  </reference>
  <reference>
    <citation>Mustard JF, Moore S, Packham MA, Kinlough-Rathbone RL. Platelets, thrombosis and atherosclerosis. Prog Biochem Pharmacol. 1977;13:312-25.</citation>
    <PMID>928433</PMID>
  </reference>
  <reference>
    <citation>Mustard JF, Packham MA, Kinlough-Rathbone RL. Platelets and thrombosis in the development of atherosclerosis and its complications. Adv Exp Med Biol. 1978;102:7-30. Review.</citation>
    <PMID>356564</PMID>
  </reference>
  <reference>
    <citation>Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999 Aug 24;100(8):793-8.</citation>
    <PMID>10458713</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973-9. Erratum in: N Engl J Med 1997 Jul 31;337(5):356.</citation>
    <PMID>9077376</PMID>
  </reference>
  <reference>
    <citation>Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004 Sep 21;110(12):1706-8. Review.</citation>
    <PMID>15381661</PMID>
  </reference>
  <reference>
    <citation>Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997 Apr;77(4):333-7.</citation>
    <PMID>9155612</PMID>
  </reference>
  <reference>
    <citation>Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002 Jan 22;105(3):387-92.</citation>
    <PMID>11804997</PMID>
  </reference>
  <reference>
    <citation>Oberle S, Polte T, Abate A, Podhaisky HP, Schröder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998 May 18;82(9):1016-20.</citation>
    <PMID>9598599</PMID>
  </reference>
  <reference>
    <citation>Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schröder H. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003 Sep 5;308(4):956-60.</citation>
    <PMID>12927812</PMID>
  </reference>
  <reference>
    <citation>Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997 Oct 21;96(8):2751-3.</citation>
    <PMID>9355934</PMID>
  </reference>
  <reference>
    <citation>U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002 Jan 15;136(2):157-60.</citation>
    <PMID>11790071</PMID>
  </reference>
  <reference>
    <citation>Hennekens CH, Hollar D, Baigent C. Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nat Clin Pract Cardiovasc Med. 2006 Jan;3(1):4-5.</citation>
    <PMID>16391594</PMID>
  </reference>
  <reference>
    <citation>Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002 Jul 16;106(3):388-91. Review.</citation>
    <PMID>12119259</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2006</study_first_posted>
  <results_first_submitted>May 16, 2012</results_first_submitted>
  <results_first_submitted_qc>May 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary prevention</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From Dec 2006 through May 2007, 70 eligible subjects were randomized from a primary care clinical site under the direction of Alex Pokov, MD.</recruitment_details>
      <pre_assignment_details>In this trial there was no wash-out or run-in period, as all eligible subjects were not taking aspirin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 of 5 Randomized Treatment Arms</title>
          <description>81 mg Aspirin</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 of 5 Randomized Treatment Arms</title>
          <description>162 mg Aspirin</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 of 5 Randomized Treatment Arms</title>
          <description>325 mg Aspirin</description>
        </group>
        <group group_id="P4">
          <title>Arm 4 of 5 Randomized Treatment Arms</title>
          <description>650 mg Aspirin</description>
        </group>
        <group group_id="P5">
          <title>Arm 5 of 5 Randomized Treatment Arms</title>
          <description>1300 mg Aspirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 of 5 Randomized Treatment Arms</title>
          <description>81 mg Aspirin</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 of 5 Randomized Treatment Arms</title>
          <description>162 mg Aspirin</description>
        </group>
        <group group_id="B3">
          <title>Arm 3 of 5 Randomized Treatment Arms</title>
          <description>325 mg Aspirin</description>
        </group>
        <group group_id="B4">
          <title>Arm 4 of 5 Randomized Treatment Arms</title>
          <description>650 mg Aspirin</description>
        </group>
        <group group_id="B5">
          <title>Arm 5 of 5 Randomized Treatment Arms</title>
          <description>1300 mg Aspirin</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="10.3"/>
                    <measurement group_id="B2" value="57.0" spread="10.0"/>
                    <measurement group_id="B3" value="55.5" spread="9.2"/>
                    <measurement group_id="B4" value="58.0" spread="9.6"/>
                    <measurement group_id="B5" value="59.1" spread="11.4"/>
                    <measurement group_id="B6" value="57.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inflammatory Markers From Baseline to 3 Months</title>
        <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Platelet Biomarkers From Baseline to 3 Months</title>
        <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Nitric Oxide Formation From Baseline to 3 Months</title>
        <description>Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation.</description>
        <time_frame>Baseline to 3 Months (90-97 days)</time_frame>
        <population>Complete baseline and follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 of 5 Randomized Treatment Arms</title>
            <description>81 mg Aspirin</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 of 5 Randomized Treatment Arms</title>
            <description>162 mg Aspirin</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 of 5 Randomized Treatment Arms</title>
            <description>325 mg Aspirin</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 of 5 Randomized Treatment Arms</title>
            <description>650 mg Aspirin</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 of 5 Randomized Treatment Arms</title>
            <description>1300 mg Aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nitric Oxide Formation From Baseline to 3 Months</title>
          <description>Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation.</description>
          <population>Complete baseline and follow-up data</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="4.9"/>
                    <measurement group_id="O2" value="27.0" spread="4.4"/>
                    <measurement group_id="O3" value="31.4" spread="9.8"/>
                    <measurement group_id="O4" value="25.7" spread="3.4"/>
                    <measurement group_id="O5" value="28.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 of 5 Randomized Treatment Arms</title>
          <description>81 mg Aspirin</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 of 5 Randomized Treatment Arms</title>
          <description>162 mg Aspirin</description>
        </group>
        <group group_id="E3">
          <title>Arm 3 of 5 Randomized Treatment Arms</title>
          <description>325 mg Aspirin</description>
        </group>
        <group group_id="E4">
          <title>Arm 4 of 5 Randomized Treatment Arms</title>
          <description>650 mg Aspirin</description>
        </group>
        <group group_id="E5">
          <title>Arm 5 of 5 Randomized Treatment Arms</title>
          <description>1300 mg Aspirin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles H. Hennekens, M.D.</name_or_title>
      <organization>Florida Atlantic University</organization>
      <email>chenneke@fau.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

